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Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid through cytochrome
P450 (CYP) epoxygenases have many biological functions. Importantly, CYP epoxygenase-
derived EETs are involved in the maintenance of cardiovascular homeostasis. In fact, in
addition to their potent vasodilating effect, EETs have potent anti-inﬂammatory properties,
inhibit platelet aggregation, promote ﬁbrinolysis, and reduce vascular smooth muscle
cell proliferation. All EETs are metabolized to the less active dihydroxyeicosatrienoic
acids by soluble epoxide hydrolase (sEH). Numerous evidences support the role of
altered EET biosynthesis in the pathophysiology of hypertension and suggest the utility
of antihypertensive strategies that increase CYP-derived EET or EET analogs. Indeed,
a number of studies have demonstrated that EET analogs and sEH inhibitors induce
vasodilation, lower blood pressure and decrease inﬂammation. Some of these agents
are currently under evaluation in clinical trials for treatment of hypertension and diabetes.
However, the role of CYP epoxygenases and of the metabolites generated in cancer
progression may limit the use of these drugs in humans.
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EPOXYEICOSATRIENOIC ACIDS: SYNTHESIS AND
METABOLISM
Arachidonic acid (AA) is a polyunsaturated omega-6 fatty acid
which is released from the sn2 position of membrane phos-
pholipids by the activity of phospholipases (PLs) and among
them it is noteworthy the role of cytosolic(c)PLA2. Free AA
can be metabolized to eicosanoids through three major path-
ways: (i) the cyclooxygenase (COX) pathway, which generates
prostanoids; (ii) the lipoxygenase (LOX) pathway, which gen-
erates leukotrienes and hydroxyeicosatetraenoic acids (HETEs);
(iii) the cytochrome P450 (CYP) pathway, which includes CYP
epoxygenase and CYPω-hydroxylase enzymes (Wang and Dubois,
2012; Oni-Orisan et al., 2014). CYP epoxygenases, such as mem-
bers of the CYP2C and CYP2J families, metabolize AA to four
biologically active epoxyeicosatrienoic acids (EETs; 5, 6-EET,
8, 9-EET, 11, 12-EET, and 14, 15-EET; Figure 1). Among the
members of the CYP2C and CYP2J families of CYP enzymes,
CYP2J2, CYP2C8, and CYP2C9 are the predominant epoxyge-
nase isoforms that convert AA into EETs. CYP ω-hydroxylases
convert AA to HETEs. CYP4A and CYP4F enzymes mainly cat-
alyze the ω-hydroxylation of AA to 20-HETE (Powell et al., 1998;
Figure 1). In addition, CYP1A1, CYP1B1, and CYP2E1 were
reported to catalyze the formation of different regioisomers of
HETEs.
EETs are synthesized by cells which express CYP epoxyge-
nase activity. The CYP epoxygenase inserts an oxygen atom on
a carbon attached to one of the double bonds of AA, and the dou-
ble bond is reduced as the epoxide forms (Spector, 2009). Each
CYP epoxygenase produces several regioisomers, with one form
usually predominating. Each regioisomer contains two R/S enan-
tiomeric forms in different proportions (Spector, 2009). Because
the regioisomers have a number of similar metabolic and func-
tional properties, all the EETs can be generally considered as a
single class of compounds, even if some qualitative differences
in the actions of the various regioisomers exist (Spector, 2009).
All EETs are then further metabolized by soluble epoxide hydro-
lase (sEH, EC 3.3.2.7–11; Wang and Dubois, 2012; Bellien and
Joannides, 2013), which acts by opening epoxides to diols by the
addition of water, forming the less active dihydroxyeicosatrienoic
acids (DHETs). This conversion of EET to DHET by sEH atten-
uates most biological effects of EETs, making sEH a target for
increasing and prolonging the actions of EETs (Spector, 2009). In
addition, EETs undergo β-oxidation, forming 16-carbon epoxy-
derivatives that accumulate in the extracellular ﬂuid, and they can
be chain-elongated to form22-carbonderivatives that are incorpo-
rated into phospholipids. EETs are also readily incorporated into
cellular membranes via esteriﬁcation to phospholipids for subse-
quent release by phospholipases (Spector, 2009). Endothelial cells
are a major site of EET incorporation, primarily acylated at the sn2
position of phospholipids and capable of being released by PLA2
(Weintraub et al., 1999).
BIOLOGICAL EFFECTS OF EETs
Epoxygenase enzymes are localized in endothelial and vascular
smooth muscle cells, and also in astrocytes and cardiomyocytes
(Imig, 2012; Wang and Dubois, 2012; Oni-Orisan et al., 2014).
While 20-HETE is a vasoconstrictor, EETs are vasodilators, except
in the pulmonary bed (Bellien and Joannides, 2013). The mecha-
nisms of EET-induced vasodilatation are complex, but increasing
evidences have suggested the involvement of endothelial and
smooth muscle membrane receptors (Bellien et al., 2011; Chen
et al., 2011). In fact, EETs are able to diffuse from the endothelial
cells to activate large conductance calcium-activated potassium
(BKCa) channels located on the smooth muscle cells, causing their
hyperpolarization and relaxation. Then, the endothelial hyperpo-
larization is transmitted to the smooth muscle through the gap
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FIGURE 1 |The cascade of arachidonic acid (AA). AA is a polyunsaturated
omega-6 fatty acid which is released from the sn2 position of membrane
phospholipids by the activity of cPLA2. Free AA can be metabolized to
eicosanoids through three major pathways: the cyclooxygenase (COX)
pathway, the lipoxygenase (LOX) pathway, and the cytochrome P450 (CYP)
pathway. In the CYP pathway, AA is converted to epoxyeicosatrienoic acids
(EETs) and 20-HETE by CYP epoxygenases and CYP ω-hydroxylases,
respectively. All EETs are then further metabolized by soluble epoxide
hydrolase (sEH) forming the less active dihydroxyeicosatrienoic acids
(DHETs). Modiﬁed from Imig and Hammock (2009).
junctions, or the accumulation of K+ released from the endothe-
lial KCa channels into the myoendothelial space induces smooth
muscle hyperpolarization by the activation of inward rectifying
potassium channels and/or Na+/K+-ATPase (Archer et al., 2003;
Huang et al., 2005). The potent vasodilatory effects of EETs are
more pronounced in the presence of inhibition of prostacyclin
and nitric oxide biosynthesis (Deng et al., 2010). For all of these
reasons, CYP-derived EETs are considered as one of the primary
endothelium-derivedhyperpolarizing factors (EDHFs; Bellien and
Joannides, 2013).
Recently, in addition to maintain vascular tone, it has been
established a further role of CYP epoxygenase-derived EETs in the
maintenance of cardiovascular homeostasis (Figure 2). In fact,
EETs induce vasodilation and exert anti-inﬂammatory effects in
blood vessels in an autocrine manner (Fleming, 2008), limiting
leukocyte adhesion and transmigration across the endothelium,
inhibiting platelet aggregation, promoting ﬁbrinolysis, and reduc-
ing vascular smooth muscle cell proliferation (Figure 2; Fleming,
2008; Deng et al., 2010; Bellien and Joannides, 2013). EETs can
protect the myocardium and brain from ischemia, attenuate
hypertension-induced renal damage, and reduce cigarette smoke-
induced lung inﬂammation (Figure 2; Imig and Hammock,
2009; Deng et al., 2010; Wang and Dubois, 2012). EETs control
these different functions by inducing endothelial cell prolifera-
tion, survival, and stimulating renal epithelial cell proliferation
and survival through multiple signaling pathways (Xu et al., 2011).
EETs play a role in the regulation of intracellular Ca2+ levels and
endoplasmic reticulumhomeostasis, through the expression of the
sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2a)
which transfers Ca2+ from the cytosol of the cardiomyocyte to
the lumen of the sarcoplasmic reticulum during muscle relaxation
(Wang et al., 2014).
In addition, EETs play important roles in the regulation of
angiogenesis and in the control of metabolic processes (Figure 2;
Fleming, 2007; Lorthioir et al., 2012). Moreover, recent emerging
evidences have indicated that EETs are involved in cancer biology;
in fact, it has been shown that EETs are critical for primary tumor
growth and metastasis, by directly promoting cancer cell prolifera-
tion, survival, migration and invasion (Figure 2; Jiang et al., 2007;
Panigrahy et al., 2012; Wang and Dubois, 2012).
EETs IN CARDIOVASCULAR DISEASE
HYPERTENSION
Many evidences suggest that alteration in EET pathway contribute
to the pathophysiology of hypertension, including blood pres-
sure elevation, endothelial dysfunction and end-organ damage.
The infusion of angiotensin II (Ang II), a potent vessel con-
strictor, elevates blood pressure in various animal models (Imig
et al., 2002). It has been established that Ang II stimulates 20-
HETE synthesis in renal microvessels and decreases EET levels
by downregulating epoxygenases and increasing their degrada-
tion by increasing expression and activity of sEH (Croft et al.,
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FIGURE 2 | Biological effects of EETs.
2000; Alonso-Galicia et al., 2002; Ai et al., 2007). In addition,
numerous animal studies have established the role EETs in blood
pressure regulation. Mice lacking the sEH gene (epoxide hydro-
lase 2, Ephx2−/−) have signiﬁcantly higher circulating EET levels
and lower blood pressure when compared with wild-type mice.
Renal production of DHETs was decreased and EET formation
increased in the Ephx2−/−mice, suggesting an important role for
epoxygenase metabolism in the regulation of blood pressure (Sinal
et al., 2000). In addition, the administration of a sEH inhibitor
(sEHI) signiﬁcantly lowers blood pressure in various rodent mod-
els of hypertension (Sinal et al., 2000; Manhiani et al., 2009). The
administration of a single dose of a sEH inhibitor [sEHI; N,N ′-
dicyclohexyl urea (DCU)] to Ang II-infused rats greatly increased
the level of EETs, decreased urinary DHET excretion, and lowered
systolic blood pressure, thus reversing the hypertensive phenotype
typical of the spontaneously hypertensive rats (Yu et al., 2000; Imig
et al., 2002). Moreover, reduced myogenic constriction in the arte-
rioles of Ephx2−/− mice has been recently found (Sun et al., 2014).
This effect was mediated by increased endothelial EET bioavail-
ability which potentiates vasodilator responses that counteract
pressure-induced vasoconstriction to lower blood pressure.
The central role of renal sEH in the development of hyper-
tension is also sustained by the ﬁnding that kidneys of the
spontaneously hypertensive rats have increased expression of sEH
and urinary DHET excretion (Imig et al., 2002). Moreover, Kujal
et al. (2014) have recently shown that renin (Ren)-2 transgenic
rats (TGR) after 5/6 renal mass reduction (i.e., a model of chronic
kidney disease associated with Ang II-dependent hypertension),
exhibit a profound deﬁciency of intrarenal availability of EETs,
that was mitigated by the use of a sEH inhibitor [cis-4-[4-(3-
adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid c-(AUCB)].
This phenomenon was associated with renoprotective actions.
Renovascular disease (RVD) represents a relatively rare form of
secondary hypertension; it is associated with increased cardiovas-
cular mortality and it is one of the prevalent causes of end-stage
renal failure (Johansson et al., 1999; Fatica et al., 2001). InRVD, the
activationof the renin-angiotensin system leads to increasedAng II
activity which contributes to vasoconstriction, increased endothe-
lin release, vascular remodeling, extracellular matrix deposition,
and accelerated atherogenesis and glomerulosclerosis (Kim and
Iwao, 2000). This disease is strictly associated with enhanced lipid
peroxidation related to activation of the renin-angiotensin system
(Minuz et al., 2002). In patients with RVD-associated hyperten-
sion, it has been found a decrease in EET plasma levels that
supports a pivotal role of EETs in vascular homeostasis (Minuz
et al., 2008). Interestingly, the ratio of plasma EETs:DHETs, which
provides an index of the activity of sEH was reduced in patients
with RVD or with essential hypertension compared to control
subjects, suggesting the increase of sEH activity. In contrast to
EETs, plasma 20-HETE levels were higher in patients with RVD
compared to subjects with essential hypertension and healthy
controls. In RVD, plasma 20-HETE signiﬁcantly correlated with
plasma renin activity, thus suggesting its role in the elevation
of blood pressure through the possible increase of vasomotion
and vascular reactivity (McGiff and Quilley, 1999). A signiﬁcant
reduction of the urinary excretion of 20-HETE was detected in
RVD (Minuz et al., 2008). This ﬁnding may reﬂect a decrease in
20-HETE production by the thick ascending limb and proximal
tubules which may lead to increased Na+ reabsorption in these
tubular segments.
In pregnancy-induced hypertension, the urinary excretion of
DHETs is increased versus healthy pregnant women which may
implicate an increased degradation of EETs (Catella et al., 1990).
Differently, Jiang et al. (2013) found a decreased urinary excretion
of DHETs in preeclampsia which can be interpreted as evidence of
deﬁcient renal EET formation in preeclamptic pregnancy. How-
ever, direct comparison of the two studies is complicated by the
severity of hypertension and clinical conditions of patients in the
study by Catella et al. (1990; mean blood pressure 182/112 mmHg,
reduced platelet count).
Plasma EET levels are higher in preeclamptic and normoten-
sive pregnant women than in non-pregnant controls (Jiang et al.,
2013). Furthermore, plasma levels of EETs are 3-fold higher in fetal
than in maternal blood. Altogether these results suggest that the
vasodilatatory and antiinﬂammatory activities of EETs may rep-
resent the basis for cellular protective actions in the fetoplacental
unit and vascular homeostasis in pregnancy (Jiang et al., 2013).
Some genetic evidences in humans have supported the crucial
role of the epoxygenase pathway inhypertension (Fava et al., 2012).
In fact, it has been found that a single nucleotide polymorphism
(SNP) in the CYP2J2 gene (the CYP2J2*7 genotype) was associ-
ated with hypertension in males, but not in females of a Caucasian
population (King et al., 2005). It is known that the SNP CYP2J2*7
interferes with a binding site for the transcription factor Sp1 with
consequent reduction in the plasma levels of EETs in vivo (King
et al., 2002; Spiecker et al., 2004). In addition, CYP2C8, CYP2C9,
and also EPHX2 genetic variants have been associated to myocar-
dial infarction and cardiovascular disease (Spiecker et al., 2004;
Marciante et al., 2008).
CORONARY ARTERY DISEASE AND OTHER CARDIOVASCULAR RISK
FACTORS
Increased EET plasma levels were observed in patients with sta-
ble angiographically conﬁrmed coronary artery disease (CAD;
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Theken et al., 2012), without any modiﬁcation in DHET level,
suggesting that, in these particular conditions, an upregulation
of CYP epoxygenase activity/expression may serve as a defensive
mechanism.
In a population of patients with stable, angiographically con-
ﬁrmed CAD and healthy, Theken et al. (2012) aimed to identify
clinical factors that inﬂuence CYP epoxygenase, sEH, and CYP
ω-hydroxylase metabolism. Obesity was signiﬁcantly associated
with low plasma EET levels and 14,15-EET:14,15-DHET ratios
(a biomarker of sEH metabolism). Age, diabetes, and cigarette
smoking also were signiﬁcantly associated with CYP epoxygenase
and sEH metabolic activity, while only renin-angiotensin system
inhibitor use was associated with CYP ω-hydroxylase metabolic
activity. Compared to healthy volunteers, both obese and non-
obese CAD patients had signiﬁcantly higher plasma EETs and
epoxide:diol ratios, whereas no difference in 20-HETE levels was
observed (Theken et al., 2012). Collectively, these ﬁndings sug-
gest that CYP-mediated eicosanoid metabolism is dysregulated in
certain subsets of CAD patients, and demonstrate that biomark-
ers of CYP epoxygenase and sEH, but not CYP ω-hydroxylase,
metabolism are altered in stable CAD patients relative to healthy
individuals.
Recently, it was found a protective role of CYP2J2-derived EETs
in heart failure (Wang et al., 2014). Thus CYP2J2-derived EETs
may be a target for the development of drugs to prevent cardiac
hypertrophy and cardiomyocyte apoptosis in heart failure.
PHARMACOLOGICAL STRATEGIES TO MODULATE
CYP-DERIVED EPOXYEICOSATRIENOIC ACIDS PATHWAY
The generation of transgenic mice with endothelial expression of
the human CYP2J2 and CYP2C8 epoxygenases, thus leading to
increased endothelial EET biosynthesis, has proved that endothe-
lial CYP epoxygenases regulate blood pressure. In fact, these mice
exhibit enhanced afferent arteriolar dilation, lower blood pressure
and attenuated hypertension-induced renal injury compared to
wild-type (Lee et al., 2010). These ﬁndings suggest the potential
therapeutic utility of antihypertensive strategies that may increase
CYP-derived EETs.
Different pharmacological strategies have been developing to
increase EET availability: (i) the administration of EET analogs;
(ii) the inhibition of EET catabolism by sEH inhibitors.
Epoxyeicosatrienoic acid analogs (designed to resistmetabolism
and improve their solubility) have been synthesized and have
permit to determine EET structure function relationships and
deﬁne the physiological roles of each EET regioisomer in
the cardiovascular system (Sudhahar et al., 2010). Recently, it
has been selected a 11,12-EET analog capable to lower blood
pressure in spontaneously hypertensive rats (Sudhahar et al.,
2010), supporting the use of EETs analog in the treatment of
hypertension.
sEH inhibitors are efﬁcacious antihypertensive agents in the
Ang II-dependent animal model, a model of human essential
hypertension (Imig et al., 2002; Bellien et al., 2011; Imig, 2012).
In addition to their efﬁcacy in lowering blood pressure, sEH
inhibitors improve endothelial function and reduce hypertension-
induced renal injury and cardiac hypertrophy/dysfunction. More-
over, an increasing number of studies have also shown the
beneﬁcial effects of sEH inhibitors in other cardiovascular
disorders, including ischemia–reperfusion, heart failure, and
atherosclerosis (Zhang et al., 2009; Bellien et al., 2011; Merabet
et al., 2012).
Among numerous synthesized sEH inhibitors, AR9281 [1-(1-
acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea; Imig and Ham-
mock, 2009; Anandan et al., 2011] was selected for phase 1 clinical
trial. AR9281 showed a safety proﬁle and it directly and dose-
dependently inhibited blood sEH activity, in healthy subjects
(Chen et al., 2012). Its efﬁcacy in patients with hypertension and
type 2 diabetes has been evaluated in phase II clinical trials, which
results are not yet published, even if the trial was completed in
2009 (http://clinicaltrials.gov/show/NCT00847899).
POTENTIAL ADVERSE EFFECTS IN TARGETING CYP-DERIVED
EPOXYEICOSATRIENOIC ACID PATHWAY
Potential adverse effects of pharmacological modulation of CYP-
derived EETs pathway have to be taken into account during the
development of a sEH inhibitor for the treatment of cardiovascular
disease.
Adverse events may occur in the pulmonary vasculature. In
fact, EETs, generated in vascular smooth muscle cells, increase
intracellular Ca2+, thus inducing vasoconstriction and increas-
ing pulmonary artery pressure (Bellien and Joannides, 2013).
It has been shown that sEH inhibitors can exacerbate hypoxic
pulmonary vasoconstriction, and hypoxia induced pulmonary
vascular remodeling (Pokreisz et al., 2006; Keserü et al., 2008).
Increased pulmonary vasoconstriction in response to hypoxia was
evidenced in Ephx2−/− mice. However, 14, 15-EET is able to con-
trast TNF-α induced hyper-reactivity in human airway smooth
muscle cells (Imig, 2012). Altogether these results suggest that
sEH inhibitors are potentially associatedwith pulmonary vasocon-
striction, but they can be beneﬁcial in the treatment of bronchial
inﬂammation (Imig, 2012).
Other potential unwanted cardiovascular effects may limit the
therapeutic use for sEH inhibitors. In fact, even if sEH inhibitors
can improve cardiac function following ischemia, they delay blood
pressure recovery after cardiopulmonary resuscitation in mice
and this effect was associated with higher mortality (Imig, 2012).
Moreover, it has been found that EETs inhibit platelet aggregation
(Heizer et al., 1991) and can hyperpolarize platelets and inacti-
vate them by inhibiting adhesion molecule expression. They can
inhibit platelet adhesion to cultured endothelial cells (Krötz et al.,
2004), thus resulting in enhanced bleeding and hemorrhaging in
patients taking sEH inhibitors.
sEH inhibitors can promote angiogenesis, resulting in accel-
eration of tumorigenesis (Michaelis et al., 2005; Fleming, 2007;
Panigrahy et al., 2011; Xu et al., 2011; Imig, 2012). In fact,
Panigrahy et al. (2012) have recently demonstrated that EETs
have a potent stimulatory effect on primary tumor growth and
tumor angiogenesis. Moreover, elevated EETs triggered extensive
metastatic spread and escape from tumor dormancy in several
tumor models (Panigrahy et al., 2012). In particular, in Tie2-CYP
transgenic mice, a transgenic model engineered to raise endothe-
lial EET levels, tumors that rarely metastasize, exhibit extensive
metastatic spread into the majority of organs. The exogenous
administration of EETs induces multiorgan metastasis and tumor
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dormancy escape in a variety of transplantable and genetically
engineered cancer models. In contrast, the administration of EET
antagonists reduced tumor growth and metastasis, prolonging
mice survival (Panigrahy et al., 2012).
CONCLUSION
Epoxyeicosatrienoic acids have many biological functions which
contribute importantly to vascular physiology and to maintain
cardiovascular homeostasis (Archer et al., 2003; Imig, 2012; Bellien
and Joannides, 2013; Oni-Orisan et al., 2014). Thus, the increase
in EET availability is emerged as a new therapeutic opportunity
in the clinical management of patients at high cardiovascular risk.
However, the use of EETs analogs and sEH inhibitors is limited
due to the recent evidences that EETs also promote tumor growth
and metastasis (Figure 2; Michaelis et al., 2005; Jiang et al., 2007;
Panigrahy et al., 2011, 2012; Bellien and Joannides, 2013).
Appropriate clinical studies should be performed to character-
ize the safety proﬁle of these novel classes of drugs before they
can be considered for the treatment of cardiovascular disease in
humans.
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